// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

P2RY6-/- MICE EXHIBIT EXACERBATED INTESTINAL INFLAMMATION ASSOCIATED WITH TH1/TH17 RECRUITMENT

Mabrouka Salem - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Sodium sulfate

NTPDASE8 PROTECTS MICE FROM INTESTINAL INFLAMMATION THROUGH REGULATION OF P2Y6 RECEPTOR ACTIVATION

Joanna Lecka - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Sodium sulfate

PREOPERATIVE USTEKINUMAB TREATMENT IS NOT ASSOCIATED WITH INCREASED POSTOPERATIVE COMPLICATIONS IN Crohn's DISEASE: A CANADIAN MULTICENTRE CASE-CONTROL COHORT STUDY

Christopher Ma - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Oraprine

EBV STATUS AND IMMUNOSUPPRESSANT USE IN PATIENTS WITH IBD WHO SUBSEQUENTLY DEVELOP LYMPHOMA: A RETROSPECTIVE AND PROSPECTIVE STUDY

Lindsy Ambrosio - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Methotrexate

INCIDENCE OF PNEUMONIA AND OTHER RESPIRATORY TRACT INFECTIONS WITH VEDOLIZUMAB TREATMENT FOR INFLAMMATORY BOWEL DISEASE: CLINICAL TRIAL EXPERIENCE

Fatima Bhayat - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

THE INCIDENCE OF CARDIOVASCULAR EVENTS IN PATIENTS WITH Crohn's DISEASE TREATED WITH VEDOLIZUMAB AND ANTI-TNF THERAPIES

Mark T. Osterman - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

EVALUATION OF SAFETY AND EFFICACY OF ANTITNF_ TREATMENT AMONG 11275 PREGNANCIES OCCURRING IN 8726 WOMEN WITH IN INFLAMMATORY BOWEL DISEASES. STUDY ON THE FRENCH NATIONAL HEALTH INSURANCE DATABASE

Eric Benzenine - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adalimumab

COMBINING PATIENT PREFERENCES AND COMPARATIVE EFFECTIVENESS RESEARCH TO INFORM TREATMENT APPROACHES FOR MAINTENANCE THERAPY IN Crohn's DISEASE

Pauline Hull - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Oraprine

LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR Crohn's DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH TWO YEARS

Paul Rutgeerts - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ustekinumab

EFFECT OF MAINTENANCE USTEKINUMAB ON CORTICOSTEROID-FREE CLINICAL OUTCOMES IN PATIENTS WITH Crohn's DISEASE

Christopher Gasink - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ustekinumab

ADHERENCE TO AN ANTI-INFLAMMATORY DIET PREVENTS INCREASES IN COLONIC INFLAMMATION IN ULCERATIVE COLITIS PATIENTS IN REMISSION

Karen Madsen - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Pyruvic acid

ETROLIZUMAB TREATMENT IMPROVES HISTOLOGICAL ACTIVITY AS ASSESSED BY THE ROBARTS HISTOPATHOLOGY INDEX

Gert De Hertogh - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Etrolizumab

EFFICACY AND SAFETY OF ABRILUMAB (AMG 181/MEDI 7183) THERAPY FOR MODERATE TO SEVERE Crohn's DISEASE

Marcoli Cyrille - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

MEDI7183

FILGOTINIB (GLPG0634, GS-6034), A JAK-1 SELECTIVE INHIBITOR, SIGNIFICANTLY REDUCES GUT TISSUE PSTAT3 IN Crohn's DISEASE PATIENTS

Brian G. Feagan - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Filgotinib

A PHASE 1/2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE INDUCTION OF CLINICAL RESPONSE AND REMISSION BY QBECO IN SUBJECTS WITH MODERATE TO SEVERE Crohn's DISEASE

Simon Sutcliffe - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

ETROLIZUMAB TREATMENT LEADS TO EARLY IMPROVEMENT IN SYMPTOMS AND INFLAMMATORY BIOMARKERS IN ANTI-TNF-REFRACTORY PATIENTS IN THE OPEN-LABEL INDUCTION COHORT OF THE PHASE 3 HICKORY STUDY

Brian G. Feagan - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Etrolizumab

APPROPRIATENESS OF CONCOMITANT IMMUNOMODULATOR AND BIOLOGIC THERAPY IN Crohn's DISEASE AND ULCERATIVE COLITIS

Gilaad Kaplan - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Oraprine

HISTOLOGICAL REMISSION IS PREDICTIVE OF IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OLE

Brian G. Feagan - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Ozanimod

THE SENSITIVITY AND SPECIFICITY OF NON-INVASIVE BLOOD-BASED TESTS AND HISTOPATHOLOGY FOR DETECTING CYTOMEGALOVIRUS REACTIVATION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Tushar Shukla - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

LONG-TERM EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 5-YEAR CUMULATIVE EXPOSURE OF GEMINI 1 COMPLETERS ROLLING INTO THE GEMINI OPEN-LABEL EXTENSION STUDY

Jean Frederic Colombel - Digestive Disease Week (DDW) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Copyright © 2026. QuantiNova All rights reserved